Aims: Conventional dorsal root ganglion stimulation (DRGS) is known to achieve better pain-paresthesia overlap of difficult-to-reach areas like the feet compared to dorsal column spinal cord stimulation (SCS). As in painful diabetic polyneuropathy (PDPN) pain is mostly present in the feet, we hypothesized that DRGS is more effective in relieving pain in PDPN when compared to SCS.
| INTRODUC TI ON
Diabetic polyneuropathy (DPN) is a chronic, symmetric, length-dependent sensorimotor polyneuropathy and is present in up to 50% of patients with diabetes mellitus.
1 One-third of these DPN patients suffer from painful diabetic polyneuropathy (PDPN), 2 which starts in the toes and spreads into the feet, legs, and hands. 3 As PDPN can be debilitating and a severe handicap to the patient and since effectiveness of pharmacological drugs is limited, there is an urgent need for other treatment options. Conventional spinal cord stimulation of the dorsal columns (hereafter named SCS) has been shown to be such a treatment option, which as well can be supplementary to pharmacological therapy. SCS has shown to be effective on the short and long term in PDPN when pharmacological therapies have failed.
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However, conventional SCS often provides incomplete pain relief (50% pain reduction or even less), 10, 11 which is restricted to 60% of PDPN patients and leaves 40% of the patients as nonresponders.
In view of these limitations, a recently introduced and very promising option for treatment of PDPN might be conventional dorsal root ganglion stimulation. DRGS is known to achieve better pain-paresthesia overlap of difficult-to-reach areas like the feet. 13, 14 The results of a recently published retrospective case series suggest that DRGS improves painful symptoms in PDPN patients. 15 As in PDPN pain is mostly present in the feet, 16 we hypothesized that DRGS is more effective in pain relief in PDPN when compared to SCS.
In order to address this hypothesis, we implemented DRGS in an already operational and meticulously tested PDPN animal model and investigated the effectiveness of both DRGS and SCS. SCS and its resulting pain relief in streptozotocin (STZ)-induced PDPN animals have recently been described and here it was shown that SCS normalizes STZ-induced mechanical hypersensitivity. 17 SCS resulted in "a clinically relevant reduction" of mechanical hypersensitivity in 70% of PDPN animals. DRGS in animals with peripheral nerve damage and chronic neuropathic pain has been described recently. 18 DRGS did not cause any dorsal root ganglion (DRG) tissue damage as verified by histological examination and with the use of DRGS parameters closely replicating those in clinical use a significant reduction of mechanical hypersensitivity in chronic neuropathic animals was noted. 18 In order to investigate the underlying pain-relieving effect of DRGS in PDPN animals, we compared the pain-relieving effect of DRGS vs SCS in PDPN-associated mechanical hypersensitivity in STZinduced diabetic rats.
| ME THODS
This study aimed to investigate the behavioral effect (mechanical hypersensitivity as measured by paw withdrawal to von Frey filaments) of one single stimulation paradigm in PDPN: a 30-minute (min) conventional DRGS (hereafter named DRGS) being compared to a 30-min SCS in rats with PDPN. 16 This manuscript adheres to the applicable ARRIVE guidelines.
| Animals
The experiments for this study were performed using 18 female 
| Behavioral testing
Pain behavior was assessed by testing mechanical hypersensitivity based on the hind limb paw withdrawal response to von Frey filaments. Before the start of behavioral testing, rats were placed in a transparent box on an elevated mesh floor and were given 15 minutes to acclimate to the surroundings. Mechanical hypersensitivity was assessed according to the "up-down method," 20 as previously described. 17, 21 A cutoff value of 28.84 g was defined. Thereafter, the registered 50% paw withdrawal thresholds (WT), measured in grams, were multiplied by 10 000 and then logarithmically transformed to conform with Weber's law 22 and obtain a linear scale. The average of the mechanical hypersensitivity of both paws in the SCS animals of the previous study 17 was compared to the average of the mechanical hypersensitivity of the ipsilateral (stimulated) paw in the DRGS animals, as we did not expect ipsilateral DRGS to have any effects on the contralateral hind paw. 
| Inclusion of animals

| Preparation electrode for DRG stimulation
The DRGS leads were manufactured from two platinum-iridium wires of different gauges, where the larger diameter wire (0.010 in) contained the smaller center wire (0.005 in; PlasticsOne, Roanoke, VA, see Figure 1 ; see reference [ 18 ] ) that were secured together at one end in a plastic connection hub. To prepare the electrode for DRGS implantation, the insulation from the terminal portion of the larger wire was removed, and the terminal portion of the wire was folded back upon itself to produce an atraumatic tip ( Figure 1 ). The insulation was similarly removed from the tip of the smaller gauge wire, which was wrapped helically around the insulated portion of the central wire.
This design produced an axially symmetric device that was insensitive to rotational movement. We added a few spots of dental cement to stabilize the structure of the electrode and to give a place for an encircling suture to grab when securing the inserted electrode. The lead was tested with an Ohmmeter to confirm that there was no contact between the two electrode poles and that there was suitable low resistance to the terminal contacts (ie, no break in the wires; Figure 1 ).
| Implantation of DRGS device
A bipolar DRGS electrode was implanted unilaterally at the L5 DRG (adapted from reference [ 18 ]). In short: For implantation of the DRGS device, the lateral aspect of the intervertebral foramen was exposed via a paravertebral incision under general anesthesia. Subsequently, the foramen was gently opened by probing with a small, blunt nerve hook to provide a passage for the electrode to enter the foramen on the dorsolateral aspect of the DRG. Both the anode and the cathode were implanted at the L5 DRG. The electrode was secured into the transverse process caudal to the foramen using a stainless steel ligature and a small screw (diameter 0,86 mm, length 3,2 mm).
| Implantation of dorsal column SCS device
The implantation of the dorsal column SCS device has been previ- 
| SCS and DRGS
After implantation of a given device (DRGS or SCS) in the separate groups, the cables were tunneled subcutaneously through the neck of the animals, sutured to muscle and skin, and the connectors also attached to the skin. The wound was closed in layers. After implantation of the device, the rats were allowed to recover for 2 days before the start of SCS at day 3 following implantation.
The animals were stimulated in one session for 30 minutes at onset. Secondly, the mean log 10 (10 000 × 50% WT) after the start of stimulation (at 15 and 30 minutes) was compared with the mean pre-STZ log 10 (10 000 × 50% WT). Thirdly, the effect size was assessed by calculation of the difference between the pre-STZ mean log 10 (10 000 × 50% WT) and the mean log 10 (10 000 × 50%
WT) at 15 and 30, and 60 minutes after the start of stimulation.
Lastly, the percentage of responders to stimulation treatment was also calculated. A responder to stimulation was defined as an animal with an increase of the log 10 (10 000 × 50%WT) ≥ 0,2 during stimulation at 15 and 30 minutes after the start of stimulation treatment.
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| Statistical analysis
Data are presented as means and standard error of mean (SEM).
Within-group analysis of changes of mechanical WT over time was analyzed using the Wilcoxon signed-rank test. Between-group comparisons of mechanical WT and group characteristics were analyzed using the Mann-Whitney U test and Kruskal-Wallis test. Statistical significance was defined as P < 0.05.
| RE SULTS
| Description of cohorts of animals
Starting from 48 animals, which were injected with STZ, 43 developed DM (blood glucose ≥15 mmol/L; 90%). PDPN developed in 22 animals (log 10 (10 000 × 50% WT) decreased ≥0.2); 51%), and those animals were implanted with a DRGS device. Four of these 22
animals were excluded from the study, due to connector breakage (n = 2) and due to having a too high MT (>1 mA) (n = 2). The remaining 18 animals were included for this study and divided into two groups: DRGS (n = 11) and sham-DRGS (n = 7). For SCS, 11 PDPN animals were used as a historical cohort and as described by Pluijms et al 
| Development of mechanical hypersensitivity
In the SCS group, the log 10 (10 000 × 50% WT) decreased from 5412 before STZ injection to 4910 before the start of stimulation (P < 0.01).
In the DRGS group, the log 10 (10 000 × 50% WT) decreased from 5059 before STZ injection to 4376 before the start of stimulation (P < 0.01). In the sham-SCS group, the log 10 (10 000 × 50% WT)
showed a trend toward a decrease from 5404 at pre-STZ baseline to 4918 before the start of the sham-SCS therapy (P = 0.25). The log 10 (10 000 × 50% WT) in the sham-DRGS group significantly decreased from 5041 before STZ injection to 4416 before the start of sham-DRGS therapy (P < 0.05).
| Effect of SCS/DRGS on mechanical hypersensitivity
In the SCS group, stimulation resulted in an increase of the log 10 (10 000 × 50% WT) from 4910 before SCS to 5211 at t = 15 minutes (P < 0.05) and a nonsignificant trend toward an increase to 5264 at t = 30 minutes (relative to the pre-stimulation baseline P = 0.11). No differences were observed between the 15-minute and 30-minute time point with SCS (P = 0.69). After SCS was stopped, the log 10 (10 000 × 50% WT) returned to pre-SCS values at t = 60 minutes (5093 g; P = 0.20). In the DRGS group, the log 10 (10 000 × 50% WT)
increased from 4376 before the start of DRGS treatment to 4809
at t = 15 minutes (P < 0.01) and increased to 5042 at t = 30 minutes relative to the pre-stimulation baseline (P < 0.01). A significant increase was observed between the 15-min and 30-min time point with DRGS (P < 0.05). After cessation of DRGS therapy, the log 10 (10 000 × 50% WT) returned to pre-DRGS values at t = 60 minutes (4451; P = 0.90). After cessation of the stimulation (t = 60 minutes) the washout effect, the log 10 (10 000 × 50% WT) with DRGS was significantly lower than that of SCS (P < 0.05) (data presented as % of pre-STZ; Figure 2 ).
| Effect of sham-SCS/sham-DRGS on mechanical hypersensitivity
Sham therapy-as expected-did not result in a significant increase of the log 10 (10 000 × 50% WT) in the sham-SCS group at t = 15 minutes (4778, P = 0.75) and at t = 30 minutes (4796, P = 0.99), and neither in the sham-DRGS group at t = 15 minutes (4354, P = 0.56) and at t = 30 minutes (4382, P = 0.69). No significant differences in terms of log 10 (10 000 × 50% WT) were found between the DRGS and SCS groups (data presented as % of pre-STZ; Figure 3 ).
| Percentage responders
In the SCS cohort, the percentage of responders to stimulation was 75% (six out of eight) at t = 15 and 30 minutes, whereas in the DRGS cohort, the percentage of responders was 73% (eight out of eleven) at t = 15 minutes and 91% (ten out of eleven) at t = 30 minutes. Sham-SCS did not result in a response on mechanical hypersensitivity both at t = 15 minutes (0/3) and at t = 30 minutes (0/3), whereas sham-DRGS resulted in 1 responder only at t = 30 minutes
(1/7, 14%) ( Table 1 ).
| Effect size of SCS and DRGS: comparison with pre-STZ values
In the SCS group, the log 10 (10 000 × 50% WT) returned to pre-STZ values after t = 15 minutes (P = 0.31) and t = 30 minutes (P = 0.69).
In the DRGS group, the log 10 (10 000 × 50% WT) returned to pre-STZ values after t = 30 minutes (P > 0.99) (data presented as % of pre-STZ; Figure 2 ).
| Intergroup comparison of effect size of SCS and DRGS on mechanical hypersensitivity
Intergroup comparison of the effect size showed no differences between the SCS cohort and the DRGS cohort at 15 minutes (P = 0.30) and at 30 minutes (P = 0.13), and 60 minutes (P = 0.59) (Figures 2-4 ).
(data presented as % of pre-STZ (Figures 2-4 ).
| D ISCUSS I ON
This is the first study that analyzes the behavioral pain-relieving effect of DRGS in PDPN animals. From our results, we conclude that DRGS 
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The DRG mediates nociception from the peripheral nerves to the central nervous system 27 and is an appealing site for neurostimulation as it represents the sensory gateway to the spinal cord, containing sensory neuron somata for all sensory modalities and fiber types. At the DRG, it is theoretically possible to modulate not only the non-nociceptive A β fibers, but also the nociceptive A δ -and Ctype fibers. 25 Furthermore, the DRG is of great importance in the development and maintenance of chronic pain, as it exhibits pathophysiologic changes during chronic pain states, like altered electrophysiological membrane properties, changes in the expression of integral membrane proteins, and altered gene expression.
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Elevated excitability of sensory neurons in the DRG contributes to the pathogenesis of chronic pain that follows peripheral nerve F I G U R E 2 Effect of SCS (n = 8) and DRGS (n = 11) on mechanical hypersensitivity. Data are presented as mean % of pre-STZ log 10 (10 000 × 50% WT) ± SEM. Data are compared to pre-STZ values and pre-stimulation baseline values. The stippled area denotes the stimulation period. (also in Figure 3 ). *P < 0.05, **P < 0.01 compared to pre-STZ values; # P < 0.05, ## P < 0.01 compared to pre-SCS baseline; P < 0.05. SCS, spinal cord stimulation; DRGS, dorsal root ganglion stimulation; STZ, streptozotocin; SEM, standard error of mean; min, minutes injury, 31 and treatment at this site may interact with the pathogenic processes. It is known that DRGS reduces the generation of action potentials by the sensory neurons during membrane depolarization, which suggest that DRGS provides its analgesic effect via reducing sensory neuron excitability, both on spontaneous activation within the DRG and exerting an inhibitory influence on small diameter fiber activity passage at the T-junction.
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Conventional SCS (pulse width 0.2-0.5 ms; amplitude of 3.6-8.5 mA; frequency of 40-80 Hz) 32, 33 has been shown to be effective in patients having a variety of neuropathic pain conditions, including PDPN. [10] [11] [12] DRGS is, with proper lead placement, effective for pain localized to the back, groin, legs, and feet. 13, [34] [35] [36] While SCS is often unable to cover difficult-to-reach areas like the feet and the groin without generating extensive paresthesias or motor side effects, 13 conventional DRGS (settings: pulse width 0.2-0.4 ms; amplitude of 800-900 µA; frequency of 20-70 Hz) 13, 34 has been shown to be able to cover these difficult-to-reach areas, without generating large unwanted areas of paresthesia. DRGS offers several other potential benefits over SCS systems like lack of positional and movement effects on stimulation and reduced migration rate, because of better lead stability. 1, 13, 27 Additionally, as the anatomical location of the DRG offers a closer proximity to the electrodes compared to the spinal cord and its dorsal columns, reduced power is required. 1, 13 As PDPN pain is mostly located in the feet, we expected DRGS to be more effective for PDPN pain relief then SCS. Nevertheless, our results showed that effectiveness for pain relief with DRGS and SCS is similar in PDPN animals, with use of conventional stimulation settings. It needs to be stressed that these experiments were based on short-term stimulation paradigms. Therefore, long-term efficacy should be studied in future animal research to analyze and detect possible differences between the effect of DRGS and SCS in PDPN.
In this study, the therapeutic pain- From this study, it was concluded that Burst-SCS requires significantly more mean charge per second in order to achieve similar pain relief, as compared with conventional SCS. In humans, the amplitude in conventional DRGS is usually 4-10 times less (0.8-0.9 mA) than the amplitude used for conventional SCS (3.6-8.5 mA). On the contrary, in the current animal study, amplitudes for both SCS and DRGS were very close (67% MT, 0.19 ± 0.01 mA and 0.18 ± 0.05 mA, respectively). As our study was the first study to compare SCS and DRGS in an experimental animal model for PDPN, we preferred using similar settings for DRGS and SCS. However, we cannot completely exclude that with an amplitude of 67% MT, as in our protocol, also the dorsal columns in the spinal cord were stimulated during DRGS, thereby potentially causing a similar pain relief in the animals. The use of lower DRGS stimulation amplitudes (more like the amplitudes used clinically in humans-ie, about 15% of the conventional output of an SCS system) 34 and effect on pain relief unquestionably need to be tested in the near future.
| Limitations
For translation of our experimental data to the clinic, where longterm SCS protocols are used for treatment of pain in PDPN, we 
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